Day: July 16, 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS), AUSTRALIA, JAPAN, CANADA, HONG KONG, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR OTHER ACTION UNDER APPLICABLE LAW. OTHER RESTRICTIONS APPLY. PLEASE SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. The board of Fingerprint Cards AB (publ) (“Fingerprints” or the “Company”) has decided on an early redemption of the Company’s outstanding bond loan of MSEK 300 through a new financing amounting to at least MSEK 340 with an option to increase up to MSEK 430. As a result of the challenging market in which the Company has operated since Covid-19, the outstanding bond...

Press release – Paris, July 16, 2023 Update from Danone on its operations in Russia Danone has taken note of the decision of the Russian authorities aiming at placing Danone Russia under temporary external administration of the Russian authorities1. Danone is currently investigating the situation. On October 14, 2022, Danone launched a process to transfer the control of its EDP Business in Russia, which was progressing according to the expected schedule. Danone is preparing to take all necessary measures to protect its rights as shareholder of Danone Russia, and the continuity of the operations of the business in the interest of all stakeholders, in particular its employees. This decision has no impact on Danone’s financial guidance for 20232. o o O o o FORWARD-LOOKING STATEMENTS This press release contains certain forward-looking statements...

Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimer’s DiseaseSmall molecule varoglutamstat, with potential for meaningful safety and ease of use advantages over antibody-based therapies, continues to show encouraging safety data at therapeutic dose of 600 mg twice daily, a dose demonstrated to result in nearly 90% target occupancy VIVIAD data presented at AAIC 2023 demonstrate that WAIS-IV Coding test as an inclusion criterion successfully ensures recruitment of patients with early AD presenting with evidence of baseline cognitive deficits, enabling a more reliable assessment of potential cognitive improvement after treatment June 2023 DSMB meeting results with approval to proceed for both VIVIAD and VIVA–MIND VIVIAD Phase 2b study...

Figure 1 Acumen Pharmaceuticals, Inc.Figure 2 Acumen Pharmaceuticals, Inc.Topline results from INTERCEPT-AD trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibodyRapid, dose-related, statistically significant (p=0.01) amyloid plaque reduction observed within higher dose cohorts (25% reduction in 60 mg/kg Q4W cohort at day 63 and 20% reduction in 25 mg/kg Q2W cohort at day 70) ACU193 approached maximal central target engagement of toxic AβOs beyond expected levels, establishing broad therapeutic index and path to convenient monthly dosing ​ ACU193 was well-tolerated in patients with early Alzheimer’s disease and resulted in no drug-related serious adverse events, with a low rate of ARIA-E across all cohorts Company to host...